Biosimilar Development News
-
STEQEYMA® (ustekinumab-stba), A Biosimilar To STELARA® (ustekinumab), Now Available In The United States
3/12/2025
Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.
-
U.S. FDA Approves Celltrion's OMLYCLO® (omalizumab-igec) As The First And Only Biosimilar With Interchangeability Designation Referencing XOLAIR®
3/9/2025
Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab) for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), Immunoglobulin E (IgE)-mediated food allergy, and chronic spontaneous urticaria (CSU).
-
Biocon Biologics Announces Positive Results From Phase 3 Study Of Yesintek™ Biosimilar To Ustekinumab For Chronic Plaque Psoriasis
3/7/2025
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced the successful results of a pivotal Phase 3, randomized, double-blind, parallel group, multicenter study comparing Yesintek™ (Biocon Biologics' biosimilar to Ustekinumab, called YESINTEK) with reference product Stelara (Ustekinumab) in adult patients with moderate to severe chronic plaque psoriasis (PsO).
-
Biosimilars Canada Announces Board Chair And Vice-Chair For 2025
3/3/2025
Biosimilars Canada is pleased to announce the unanimous election of Mike Casia, President and Managing Director of Organon Canada, as Chair of Biosimilars Canada for 2025.
-
Celltrion Receives U.S. FDA Approval For STOBOCLO® (denosumab-bmwo) And OSENVELT® (denosumab-bmwo) Biosimilars Referencing PROLIA® And XGEVA®
3/3/2025
Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO® (CT-P41, denosumab-bmwo) and OSENVELT® (CT-P41, denosumab-bmwo), biosimilars referencing PROLIA® (denosumab) and XGEVA® (denosumab) respectively for all indications of reference products.
-
Sandoz Launches Biosimilar Pyzchiva® (ustekinumab-ttwe) In The US, Offering New Treatment For Around 12 Million Patients[1-4]
2/24/2025
Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announces the launch of Pyzchiva®* (ustekinumab-ttwe) in the US. From today, the medicine is commercially available to patients across the US.
-
Biocon Biologics Launches Yesintek™ (ustekinumab-kfce) Biosimilar To Stelara® In The United States
2/24/2025
Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced that YESINTEK™ (ustekinumab-kfce) is now available to patients in the United States, and is one of the first Stelara® (ustekinumab) biosimilar market entrants in the country.
-
Apotex Licenses Exclusive Canadian Rights To Qutenza® From GrĂ¼nenthal
2/24/2025
Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, and Grünenthal, a global leader in pain management and related diseases, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain.
-
Teva And Alvotech Announce SELARSDI (ustekinumab-aekn) Injection Now Available In The U.S.
2/21/2025
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced the availability of SELARSDI™ (ustekinumab-aekn) injection in the U.S., a biosimilar to Stelara® (ustekinumab), for the treatment of psoriatic arthritis, plaque psoriasis, Crohn’s disease, ulcerative colitis, pediatric plaque psoriasis and pediatric psoriatic arthritis.
-
Clinical And Translational Science Publishes Phase 1 Clinical Results Of Henlius' HLX14
2/18/2025
Recently, results from the phase 1 clinical study (NCT04534582) of Henlius’ denosumab biosimilar candidate HLX14 (a recombinant anti-RANKL human monoclonal antibody injection) was published in Clinical and Translational Science (IF 3.1).